Please assess the completion status of the following clinical trial:

Trial Title: Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Macular edema secondary to BRVO~* Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart~* Duration no shorter than 3 months~* Duration no longer than 12 months~Exclusion Criteria:~* Proliferations in study eye~* Blod in vitreous cavity~* Previous fundus laser treatment~* BRVO with over 180˚ of ischemia on FA~* Age under 18~* Other eye condition which contribute to relevant loss of visual acuity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Grid Laser
- 2 (Type: EXPERIMENTAL): Vitrectomy in combination with 20 mg triamcinolone

Based on this trial design, predict the completion outcome and termination type (if applicable).